1-20 of 61 results for subject:Donepezil
Librarians' tools
- Search time
- 0.246 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Donepezil
- We searched for
- subject_t:Donepezil OR subject_t:Aricept OR subject_ses:551685
Type
+
Members' contributions (30)
-
Business questions (1)
-
Oral answers to questions (13)
+
Oral questions (15)
-
Prime Minister's questions (1)
-
Proceeding contributions (2)
+
Parliamentary questions (47)
-
Business questions (1)
+
Oral questions (15)
-
Prime Minister's questions (1)
-
Written questions (31)
House
Session
Year
Department
Member
More
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
asked Her Majesty's Government:Why the drug Aricept is available through the National Health Service only to those who suffer from the more severe form of Alzheimer's disease.
asked Her Majesty's Government:Why the drug Aricept is available through the National Health Service only to those who suffer from the more severe form of Alzheimer's disease.
Asked by
Lord Taylor of Warwick
(Conservative)
Answered by
Lord Darzi of Denham
(Labour)
Type
Written questions
Status
Answered
Answered on
27 March 2008
On 22 November 2006, the National Institute for Health and Clinical Excellence (NICE) issued a technology appraisal on the drugs Aricept, Ebixa, Exelon and Reminyl for the treatment of Alzheimer's disease. NICE recommends the drugs Aricept, Exelon and Reminyl as an option for use in the treatment of moderate stage Alzheimer's disease only.
The NICE guidance recommends that patients already receiving the drug Aricept for either mild or more severe Alzheimer's disease can continue on them until they, their carers and/or their clinicians feel it is appropriate to stop.
Healthcare professionals are expected to take NICE's guidance into account when reaching a clinical judgment on the best treatment for their patients. The NICE guidance allows clinician's individual responsibility to make clinical decisions about individual patients.
Subjects
Alzheimer's disease; Drugs; NHS; Donepezil
Date
27 March 2008
Reference
2598; 700 c117-8WA
House
House of Lords
My right hon. Friend will be aware that some two years ago, the National Institute for Health and Clinical Excellence restricted the use of Aricept and other drugs used in the treatment of dementia and Alzheimer's disease. That decision has been subject to a judicial review and has been upheld. However, NICE has never released the data modelling on which it based its decisions and still refuses to release that model for further scrutiny. Will my right hon. Friend use his influence to persuade the institute to release that data model, so that that decision can be checked?
My right hon. Friend will be aware that some two years ago, the National Institute for Health and Clinical Excellence restricted the use of Aricept and other drugs used in the treatment of dementia and Alzheimer's disease. That decision has been subject to a judicial review and has been upheld. However, NICE has never released the data modelling on which it based its decisions and still refuses to release that model for further scrutiny. Will my right hon. Friend use his influence to persuade the institute to release that data model, so that that decision can be checked?
Asked by
Eric Illsley
(Labour)
Answering body
Prime Minister
Prime Minister's questions - 1st Supplementary
Status
Answered
Answered on
24 October 2007
I know that my hon. Friend has taken up this issue and has raised it in this House before. We established NICE so that it could make its decisions transparently, independently and free from political interference. I think that in the light of the current legal action relating to this, it would be inappropriate to comment further on the specifics of what he has said. However, I can say that the Department of Health is investing £20 million in a new national research network on neurological disease, which will expand the number and range of clinical trials on treatment. Alzheimer's disease is one of those areas that will benefit, and I hope that he will join me in welcoming this new addition to the research.
Subjects
Dementia; Alzheimer's disease; Licensing; Drugs; Donepezil
Date
24 October 2007
Reference
465 c288
Chamber / Committee
House of Commons chamber
House
House of Commons
Will my right hon. Friend intercede and ask the Government seriously to consider the recommendation of the Alzheimer’s Society that the National Institute for Health and Clinical Excellence should broaden its remit so that the second-class citizens in England who are about to be denied drugs such as Aricept for...
Will my right hon. Friend intercede and ask the Government seriously to consider the recommendation of the Alzheimer’s Society that the National Institute for Health and Clinical Excellence should broaden its remit so that the second-class citizens in England who are about to be denied drugs such as Aricept for...
Member
Michael Connarty
(Labour)
Type
Business questions
Subjects
Devolution; Alzheimer's disease; Finance; Drugs; Medical treatments; National Institute for Health and Care Excellence; Scotland; Donepezil
Date
23 November 2006
Reference
453 c694
Chamber / Committee
House of Commons chamber
House
House of Commons
I am certainly happy to consider this issue, but it is not fair to say that the Government’s remit for NICE is just about money. NICE has decided in favour of providing some drugs that are proving very costly to the NHS, but it is entirely proper that it made...
I am certainly happy to consider this issue, but it is not fair to say that the Government’s remit for NICE is just about money. NICE has decided in favour of providing some drugs that are proving very costly to the NHS, but it is entirely proper that it made...
Member
Jack Straw
(Labour)
Type
Proceeding contributions
Subjects
Devolution; Alzheimer's disease; Finance; Drugs; Medical treatments; National Institute for Health and Care Excellence; Scotland; Donepezil
Date
23 November 2006
Reference
453 c694
Chamber / Committee
House of Commons chamber
House
House of Commons
My Lords, I thank the Minister for that helpful reply. I agree that NICE plays a very important role in assessing the benefits of particular drugs and the direct costs of providing them through the NHS. But does he not agree that it is the Government’s job to set those costs against their own priorities, for example prevention of disease and early intervention, and to take into account the costs of alternative medications that are often needed and the huge cost to families, whose lives are turned upside down when Alzheimer’s strikes? Above all, there are the costs to the national economy of carers being forced out of the labour market, often on to state benefits for the rest of their life. Will the Minister agree to take all those costs into account and tell your Lordships’ House whether these drugs, at £2.50 a day, are really not cost-effective?
My Lords, I thank the Minister for that helpful reply. I agree that NICE plays a very important role in assessing the benefits of particular drugs and the direct costs of providing them through the NHS. But does he not agree that it is the Government’s job to set those costs against their own priorities, for example prevention of disease and early intervention, and to take into account the costs of alternative medications that are often needed and the huge cost to families, whose lives are turned upside down when Alzheimer’s strikes? Above all, there are the costs to the national economy of carers being forced out of the labour market, often on to state benefits for the rest of their life. Will the Minister agree to take all those costs into account and tell your Lordships’ House whether these drugs, at £2.50 a day, are really not cost-effective?
Asked by
Baroness Greengross
(Crossbench)
Oral questions - 1st Supplementary
Status
Answered
Answered on
17 October 2006
My Lords, we set up NICE with cross-party support, and it has achieved a huge international reputation. It needs to be able to carry out its difficult work free from political interference. If Ministers were to overrule NICE, it would set a dangerous and undesirable precedent.
The findings of the appraisal do not in any way suggest that the drugs concerned should not be used for moderate to severe Alzheimer’s disease, except Ebixa, a new drug that was not recommended for the treatment of moderate to severe stages. The three existing drugs continue to be recommended for moderate to severe Alzheimer’s, and the patients currently receiving all four drugs, whether routinely or as part of a clinical trial, may continue to do so until it is considered appropriate to stop. This is not a wholesale removal of those drugs from the treatment of Alzheimer’s disease.
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c649
Chamber / Committee
House of Lords chamber
House
House of Lords
Whether, in accepting the decision of the National Institute for Health and Clinical Excellence to deny Aricept to people with early stage Alzheimer’s disease, they have taken into account the full cost of the decision.
Whether, in accepting the decision of the National Institute for Health and Clinical Excellence to deny Aricept to people with early stage Alzheimer’s disease, they have taken into account the full cost of the decision.
Asked by
Baroness Greengross
(Crossbench)
Answered by
Lord Warner
(Labour)
Oral questions - Lead
Status
Answered
Procedure
Topical questions (HL)
For answer on
17 October 2006
Answered on
17 October 2006
My Lords, the National Institute for Health and Clinical Excellence has done a very thoroughjob on this difficult appraisal. It would be entirely inappropriate for the Government to second-guess NICE’s conclusions, though I know that many people will find them disappointing. The final appraisal guidance will be published next month alongside a clinical guideline on dementia, to make clear what care and support should be provided to people at all stages of Alzheimer’s disease.
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c648-9
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, the National Institute for Health and Clinical Excellence has done a very thoroughjob on this difficult appraisal. It would be entirely inappropriate for the Government to second-guess NICE’s conclusions, though I know that many people will find them disappointing. The final appraisal guidance will be published next month alongside a clinical guideline on dementia, to make clear what care and support should be provided to people at all stages of Alzheimer’s disease.
My Lords, the National Institute for Health and Clinical Excellence has done a very thoroughjob on this difficult appraisal. It would be entirely inappropriate for the Government to second-guess NICE’s conclusions, though I know that many people will find them disappointing. The final appraisal guidance will be published next month alongside a clinical guideline on dementia, to make clear what care and support should be provided to people at all stages of Alzheimer’s disease.
Answered by
Lord Warner
(Labour)
Asked by
Baroness Greengross
(Crossbench)
Type
Oral answers to questions
Whether, in accepting the decision of the National Institute for Health and Clinical Excellence to deny Aricept to people with early stage Alzheimer’s disease, they have taken into account the full cost of the decision.
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c648-9
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, we set up NICE with cross-party support, and it has achieved a huge international reputation. It needs to be able to carry out its difficult work free from political interference. If Ministers were to overrule NICE, it would set a dangerous and undesirable precedent.
The findings of the appraisal do not in any way suggest that the drugs concerned should not be used for moderate to severe Alzheimer’s disease, except Ebixa, a new drug that was not recommended for the treatment of moderate to severe stages. The three existing drugs continue to be recommended for moderate to severe Alzheimer’s, and the patients currently receiving all four drugs, whether routinely or as part of a clinical trial, may continue to do so until it is considered appropriate to stop. This is not a wholesale removal of those drugs from the treatment of Alzheimer’s disease.
My Lords, we set up NICE with cross-party support, and it has achieved a huge international reputation. It needs to be able to carry out its difficult work free from political interference. If Ministers were to overrule NICE, it would set a dangerous and undesirable precedent.
The findings of the appraisal do not in any way suggest that the drugs concerned should not be used for moderate to severe Alzheimer’s disease, except Ebixa, a new drug that was not recommended for the treatment of moderate to severe stages. The three existing drugs continue to be recommended for moderate to severe Alzheimer’s, and the patients currently receiving all four drugs, whether routinely or as part of a clinical trial, may continue to do so until it is considered appropriate to stop. This is not a wholesale removal of those drugs from the treatment of Alzheimer’s disease.
Answered by
Lord Warner
(Labour)
Type
Oral answers to questions
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c649
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, it is this Government who have adhered firmly to the principle that the NHS provides free care at the point of clinical need. If I may say so to the noble Lord, it is his Governments who from time to time have wavered on that principle, so I do not feel inclined to accept lectures on this issue from him. This Government set up NICE so that we could have a transparent, careful appraisal of the cost-effectiveness of these drugs. I thought that that had been supported by the Conservative Party. When the going gets tough, when there is an uncomfortable decision, we should support NICE, not resile from that support.
My Lords, it is this Government who have adhered firmly to the principle that the NHS provides free care at the point of clinical need. If I may say so to the noble Lord, it is his Governments who from time to time have wavered on that principle, so I do not feel inclined to accept lectures on this issue from him. This Government set up NICE so that we could have a transparent, careful appraisal of the cost-effectiveness of these drugs. I thought that that had been supported by the Conservative Party. When the going gets tough, when there is an uncomfortable decision, we should support NICE, not resile from that support.
Answered by
Lord Warner
(Labour)
Asked by
Lord Forsyth of Drumlean
(Conservative)
Type
Oral answers to questions
My Lords, does the Minister not accept that the health service once had a principle that people should be able to get the care they need regardless of ability to pay? No one is disputing that Aricept is not effective in the early stages of treatment of Alzheimer’s. What is happening is that only those who can afford to buy the drugs will get the treatment. That cannot be right, and the Minister cannot hide behind his responsibilities as a Minister to ensure that the health service does what it is supposed to do and remains true to its central principles.
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c649-50
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, does my noble friend appreciate that the families of people with Alzheimer’s disease are hungry for any kind of support? That is why there is so much emphasis on these drugs, although everyone accepts they are not effective in every case. Can the Minister give us more details about the kind of support that he mentioned in his Answer, which is to be offered to patients and families?
My Lords, does my noble friend appreciate that the families of people with Alzheimer’s disease are hungry for any kind of support? That is why there is so much emphasis on these drugs, although everyone accepts they are not effective in every case. Can the Minister give us more details about the kind of support that he mentioned in his Answer, which is to be offered to patients and families?
Asked by
Baroness Pitkeathley
(Labour)
Oral questions - Supplementary
Status
Answered
Answered on
17 October 2006
My Lords, my noble friend is right. I do not deny that we appreciate that the NICE guidance for people with Alzheimer’s disease is terribly important to their carers and clinicians. I cannot anticipate the precise terms of NICE’s clinical guideline, but it is intended to help clinicians, the public and carers to understand the best ways to meet the need for care and support, alongside drug regimes, for people who unfortunately suffer from Alzheimer’s disease.
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c650
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, does the Minister not accept that the health service once had a principle that people should be able to get the care they need regardless of ability to pay? No one is disputing that Aricept is not effective in the early stages of treatment of Alzheimer’s. What is happening is that only those who can afford to buy the drugs will get the treatment. That cannot be right, and the Minister cannot hide behind his responsibilities as a Minister to ensure that the health service does what it is supposed to do and remains true to its central principles.
My Lords, does the Minister not accept that the health service once had a principle that people should be able to get the care they need regardless of ability to pay? No one is disputing that Aricept is not effective in the early stages of treatment of Alzheimer’s. What is happening is that only those who can afford to buy the drugs will get the treatment. That cannot be right, and the Minister cannot hide behind his responsibilities as a Minister to ensure that the health service does what it is supposed to do and remains true to its central principles.
Asked by
Lord Forsyth of Drumlean
(Conservative)
Oral questions - Supplementary
Status
Answered
Answered on
17 October 2006
My Lords, it is this Government who have adhered firmly to the principle that the NHS provides free care at the point of clinical need. If I may say so to the noble Lord, it is his Governments who from time to time have wavered on that principle, so I do not feel inclined to accept lectures on this issue from him. This Government set up NICE so that we could have a transparent, careful appraisal of the cost-effectiveness of these drugs. I thought that that had been supported by the Conservative Party. When the going gets tough, when there is an uncomfortable decision, we should support NICE, not resile from that support.
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c649-50
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, my noble friend is right. I do not deny that we appreciate that the NICE guidance for people with Alzheimer’s disease is terribly important to their carers and clinicians. I cannot anticipate the precise terms of NICE’s clinical guideline, but it is intended to help clinicians, the public and carers to understand the best ways to meet the need for care and support, alongside drug regimes, for people who unfortunately suffer from Alzheimer’s disease.
My Lords, my noble friend is right. I do not deny that we appreciate that the NICE guidance for people with Alzheimer’s disease is terribly important to their carers and clinicians. I cannot anticipate the precise terms of NICE’s clinical guideline, but it is intended to help clinicians, the public and carers to understand the best ways to meet the need for care and support, alongside drug regimes, for people who unfortunately suffer from Alzheimer’s disease.
Answered by
Lord Warner
(Labour)
Asked by
Baroness Pitkeathley
(Labour)
Type
Oral answers to questions
My Lords, does my noble friend appreciate that the families of people with Alzheimer’s disease are hungry for any kind of support? That is why there is so much emphasis on these drugs, although everyone accepts they are not effective in every case. Can the Minister give us more details about the kind of support that he mentioned in his Answer, which is to be offered to patients and families?
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c650
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, I do not accept that NICE has failed to communicate its ideas properly and appropriately. It has been extremely transparent at all stages of its process in putting information on its website and into the public arena. It sends regular briefing on its work to all Members of both Houses. It has been one of the most conscientious bodies in explaining its decisions. I repeat: it has acknowledged that the three existing drugs, Aricept, Exelon and Reminyl, are recommended for the treatment of moderate to severe Alzheimer’s disease. It has not recommended that those drugs are not made available to those with that level of the disease.
My Lords, I do not accept that NICE has failed to communicate its ideas properly and appropriately. It has been extremely transparent at all stages of its process in putting information on its website and into the public arena. It sends regular briefing on its work to all Members of both Houses. It has been one of the most conscientious bodies in explaining its decisions. I repeat: it has acknowledged that the three existing drugs, Aricept, Exelon and Reminyl, are recommended for the treatment of moderate to severe Alzheimer’s disease. It has not recommended that those drugs are not made available to those with that level of the disease.
Answered by
Lord Warner
(Labour)
Asked by
Lord Addington
(Liberal Democrat)
Type
Oral answers to questions
My Lords, does the Minister not agree that we have this familiar debate every time a new type of drug or service comes up? Do the Government agree that, whatever NICE is doing, its way of explaining it to the public and politicians is failing? Can the Government give a guarantee that everyone will be brought on board in producing the new regulations, including the Plain English Campaign?
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c650-1
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, does the Minister not agree that we have this familiar debate every time a new type of drug or service comes up? Do the Government agree that, whatever NICE is doing, its way of explaining it to the public and politicians is failing? Can the Government give a guarantee that everyone will be brought on board in producing the new regulations, including the Plain English Campaign?
My Lords, does the Minister not agree that we have this familiar debate every time a new type of drug or service comes up? Do the Government agree that, whatever NICE is doing, its way of explaining it to the public and politicians is failing? Can the Government give a guarantee that everyone will be brought on board in producing the new regulations, including the Plain English Campaign?
Asked by
Lord Addington
(Liberal Democrat)
Oral questions - Supplementary
Status
Answered
Answered on
17 October 2006
My Lords, I do not accept that NICE has failed to communicate its ideas properly and appropriately. It has been extremely transparent at all stages of its process in putting information on its website and into the public arena. It sends regular briefing on its work to all Members of both Houses. It has been one of the most conscientious bodies in explaining its decisions. I repeat: it has acknowledged that the three existing drugs, Aricept, Exelon and Reminyl, are recommended for the treatment of moderate to severe Alzheimer’s disease. It has not recommended that those drugs are not made available to those with that level of the disease.
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c650-1
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, does the Minister accept that many neurologists and psychiatrists have been disappointed, as he is aware, at NICE’s recent guidance, not least because it is a matter of extremely difficult clinical judgment to tell when early Alzheimer’s disease becomes moderately severe, when the drugs may be prescribed under the NICE guidelines, and when it is advanced, when according to the guidance the drugs may not be prescribed? It is crucial that the guidance to be produced next month should be carefully examined, because the medical profession is concerned about its effects in this situation.
My Lords, does the Minister accept that many neurologists and psychiatrists have been disappointed, as he is aware, at NICE’s recent guidance, not least because it is a matter of extremely difficult clinical judgment to tell when early Alzheimer’s disease becomes moderately severe, when the drugs may be prescribed under the NICE guidelines, and when it is advanced, when according to the guidance the drugs may not be prescribed? It is crucial that the guidance to be produced next month should be carefully examined, because the medical profession is concerned about its effects in this situation.
Asked by
Lord Walton of Detchant
(Crossbench)
Oral questions - Supplementary
Status
Answered
Answered on
17 October 2006
My Lords, the noble Lord is right that this is a complex issue. That is why NICE will produce the clinical guideline next month, following consultation with a wide range of clinicians of different opinions.
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c650
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, the noble Lord is right that this is a complex issue. That is why NICE will produce the clinical guideline next month, following consultation with a wide range of clinicians of different opinions.
My Lords, the noble Lord is right that this is a complex issue. That is why NICE will produce the clinical guideline next month, following consultation with a wide range of clinicians of different opinions.
Answered by
Lord Warner
(Labour)
Asked by
Lord Walton of Detchant
(Crossbench)
Type
Oral answers to questions
My Lords, does the Minister accept that many neurologists and psychiatrists have been disappointed, as he is aware, at NICE’s recent guidance, not least because it is a matter of extremely difficult clinical judgment to tell when early Alzheimer’s disease becomes moderately severe, when the drugs may be prescribed under the NICE guidelines, and when it is advanced, when according to the guidance the drugs may not be prescribed? It is crucial that the guidance to be produced next month should be carefully examined, because the medical profession is concerned about its effects in this situation.
Subjects
Cost effectiveness; Alzheimer's disease; Drugs; NHS; National Institute for Health and Care Excellence; Donepezil
Date
17 October 2006
Reference
685 c650
Chamber / Committee
House of Lords chamber
House
House of Lords
Given that more than 40,000 people in Wales suffer from dementia and that four clinically proven drugs that have successfully treated the symptoms of Alzheimer's have been available for several years, does the Minister share my concern that National Institute for Health and Clinical Excellence withdrew the drugs solely on the ground of cost and thus ignored any consideration of quality of life? Will he get assurances from the Department of Health that NICE will co-operate fully with the Assembly's review of the drugs approval process?
Given that more than 40,000 people in Wales suffer from dementia and that four clinically proven drugs that have successfully treated the symptoms of Alzheimer's have been available for several years, does the Minister share my concern that National Institute for Health and Clinical Excellence withdrew the drugs solely on the ground of cost and thus ignored any consideration of quality of life? Will he get assurances from the Department of Health that NICE will co-operate fully with the Assembly's review of the drugs approval process?
Asked by
Jenny Willott
(Liberal Democrat)
Answering body
Wales Office
Oral questions - 1st Supplementary
Status
Answered
Answered on
15 February 2006
The advice that NICE gives is not based purely on cost—far from it. It is based on the total efficacy of a drug. In 2001, based on the information that was available at the time, NICE issued guidance saying that Aricept was suitable for prescription and an effective drug. However, further information has been provided over the past four or five years, so NICE has reviewed its advice. That is its job. It must use the best evidence available. There clearly was not a great deal of evidence at the time at which the decision was taken, but there is now more evidence. It is vital that we get the best resources from our investment in the NHS, and NICE must deal with such issues.
Subjects
Dementia; Alzheimer's disease; Health services; Finance; Licensing; Drugs; Medical treatments; Prescription drugs; National Institute for Health and Care Excellence; Wales; Testing; Side effects; Donepezil
Date
15 February 2006
Reference
442 c1403
Chamber / Committee
House of Commons chamber
House
House of Commons
To ask the Secretary of State for Health, if he will make a statement on the recommendation of the National Institute for Clinical Excellence not to use donepezil (Aricept) in the treatment of mild to moderate cases of Alzheimer's disease.
To ask the Secretary of State for Health, if he will make a statement on the recommendation of the National Institute for Clinical Excellence not to use donepezil (Aricept) in the treatment of mild to moderate cases of Alzheimer's disease.
Asked by
Roger Williams
(Liberal Democrat)
Answered by
Baroness Winterton of Doncaster
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
16 March 2005
For answer on
23 March 2005
Answered on
23 March 2005
Mr. Chope: To ask the Secretary of State for Health if he will place in the Library a copy of the Government's response to the
consultation by the National Institute for Clinical Excellence on the cost effectiveness of Arisept, Excelon and Reminyl. [222690]
Mr. Roger Williams: To ask the Secretary of State for Health if he will make a statement on the recommendation of the National
Institute for Clinical Excellence not to use donepezil (Aricept) in the treatment of mild to moderate cases of Alzheimer's disease.
[223094]
Ms Rosie Winterton: [holding answer 22 March 2005]:
I refer the hon. Members to the reply I gave my hon. Friend the Member for Monmouth (Mr. Edwards) on Wednesday 23 March.
Subjects
Alzheimer's disease; Drugs; Donepezil
Date
23 March 2005
Reference
432 c905W; 223094
House
House of Commons
To ask the Secretary of State for Health, how many NHS prescriptions for (a) Aricept, (b) Concerta XL and (c) Risperidone have been made in 2003; and what additional funds have been made available for prescription of these drugs. - Inc table.
To ask the Secretary of State for Health, how many NHS prescriptions for (a) Aricept, (b) Concerta XL and (c) Risperidone have been made in 2003; and what additional funds have been made available for prescription of these drugs. - Inc table.
Asked by
Tim Loughton
(Conservative)
Answered by
Baroness Winterton of Doncaster
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
26 November 2003
For answer on
4 December 2003
Answered on
4 December 2003
Tim Loughton: To ask the Secretary of State for Health how many NHS prescriptions for (a) Aricept, (b) Concerta XL and (c)
Risperidone have been made in 2003; and what additional funds have been made available for prescription of these drugs. [141071]
Ms Rosie Winterton: Information on the number of prescription items and net ingredient cost (NIC) of all Aricept, Concerta and
Risperidone drugs dispensed in the community in England in 2003 (January to September) is shown in the table.
National health service bodies are expected to meet the costs of prescriptions from their unified allocations, which have increased
on average by over 9 per cent., over the three years starting from 2002-03.
Number of prescription items for Aricept, Concerts and Risperidone drugs dispensed in the community in England in 2003 (January to
September 2003 only. Not a full year)
_________________________________________________________________________________________________.
Chemical name Items (000s)
Donepezil Hydrochloride (Aricept) 181.3
Concerta 93.6
Risperidone (Risperdal) 1,019.6
_________________________________________________________________________________________________.
Notes: 1. Aricept is included in British National Formulary (BNF) Section 4.11 (Drugs for dementia), and is a brand of the chemical
entity Donepezil Hydrochloride. Aricept is the only brand. There are no generics available. Concerta is included in BNF Section 4.4
(Central nervous system stimulants), and is a brand of the chemical entity Methylphenidate Hydrochloride. Concerta is one of many
brands of Methylphenidate Hydrochloride, including the generic. Risperidone is a chemical entity and is included in BNF Section 4.2
(Drugs used in psychoses and related disorders). Risperdal is the only brand of Risperdone, there are no generics available. 2. The
data are based on prescription items dispensed in the community, ie by community pharmacists and appliance contractors, dispensing
doctors, and prescriptions submitted by prescribing doctors for items personally administered in England. 3. The data do not cover
drugs dispensed in hospital or private prescriptions. 4. Doctors, dentists or nurses write prescriptions on a prescription form.
Each single item written on the form is counted as a prescription item. Source: Prescription Cost Analysis (PCA) data from the
Prescription Pricing Authority
Subjects
Alzheimer's disease; Finance; Mental illness; Prescription drugs; Prescriptions; Schizophrenia; Methylphenidate; Risperidone; Donepezil
Date
4 December 2003
Reference
415 c178W; 141071
House
House of Commons
To ask the Secretary of State for Health, how much public money has been spent on the AD2000 Study of the effectiveness of donepezil in each of the years (a) 1998, (b) 1999, (c) 2000 and (d) 2001, broken down by (i) the amount spent by individual health authorities on...
To ask the Secretary of State for Health, how much public money has been spent on the AD2000 Study of the effectiveness of donepezil in each of the years (a) 1998, (b) 1999, (c) 2000 and (d) 2001, broken down by (i) the amount spent by individual health authorities on...
Asked by
Caroline Spelman
(Conservative)
Answered by
Baroness Stuart of Edgbaston
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
13 March 2001
For answer on
19 March 2001
Answered on
19 March 2001
Mrs. Spelman: To ask the Secretary of State for Health how much public money has been spent on the AD2000 study of the effectiveness
of donepezil in each of the years (a) 1998, (b) 1999, (c) 2000 and (d) 2001, broken down by (i) the amount spent by individual
health authorities on the trial, (ii) the amount allocated to the trial from regional research and development budgets, (iii) the
amount allocated from the national research and development extra treatment costs fund and (iv) other NHS costs incurred as a result
of the trial. [154072]
Ms Stuart: [holding answer 16 March 2001]: The information is not available in the format requested.
The Department has been sponsoring a trial on the long-term effectiveness of donepezil (ARICEPT). The table shows expenditure from
the west midlands regional office of the national health service executive and the excess treatment costs budget for this trial.
£
_________________________________________________________________________________________________.
West midlands regional office Excess treatment costs
1997-98 5,000 --
1998-99 122,412 --
1999-2000 245,870 --
2000-01 225,723 145,000
2001-02 224,973 {1}200,000
_________________________________________________________________________________________________.
{1} Estimate
Subjects
Finance; Expenditure; Health authorities; NHS; Prescription drugs; Research; Clinical trials; West Midlands Health Region; Donepezil
Date
19 March 2001
Reference
365 c100-1W; 154072
House
House of Commons